For instance, loss of GPRC5D was a common finding in multiple myeloma resistance to therapy,31,32 whereas loss of BCMA was a less frequent event.33 This is hypothesized to be due to the relative importance of BCMA to the survival of the myeloma cells compared to GPRC5D. Here, TNFRSF17 is linked to plasma cell myeloma.